Inovio Pharmaceuticals financials
$1.11−5.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3K | $217.8K | $832.0K | $10.3M | $1.8M | $7.4M | $4.1M | $30.5M | $42.2M | $35.4M |
| Gross profit | $65.3K | $217.8K | $832.0K | $10.3M | $1.8M | $7.4M | $4.1M | $30.5M | $42.2M | $35.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M | -$301.2M | -$124.1M | -$111.1M | -$94.1M | -$84.6M | -$77.2M |
| Net income | -$84.9M | -$107.3M | -$135.1M | -$279.8M | -$303.7M | -$166.4M | -$119.4M | -$97.0M | -$88.2M | -$73.7M |
| Net margin | −130000.0% | −49254.3% | −16239.9% | −2726.7% | −17109.9% | −2245.4% | −2902.8% | −318.1% | −208.9% | −208.5% |
| Diluted EPS | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 | $-12.84 | $-14.52 | $-12.60 | $-13.08 | $-12.12 |
| EBITDA | -$85.4M | -$110.6M | -$130.7M | -$262.1M | -$296.5M | -$120.5M | -$105.6M | -$89.0M | -$80.9M | -$73.9M |
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M | -$215.7M | -$178.0M | -$97.9M | -$73.6M | -$63.2M | -$62.6M |
| Free cash flow | -$88.9M | -$104.6M | -$124.7M | -$217.2M | -$216.9M | -$179.5M | -$98.8M | -$75.6M | -$73.5M | -$65.3M |
| Diluted shares | 46.9M | 27.2M | 22.2M | 19.9M | 17.4M | 12.9M | 8.2M | 7.7M | 6.8M | 6.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.3M | $65.8M | $14.3M | $46.3M | $71.1M | $250.7M |
| Short-term investments | $14.2M | $28.3M | $131.0M | $206.7M | $330.2M | $160.9M |
| Total debt | $0.00 | $0.00 | $16.8M | $16.6M | $15.0M | $18.7M |
| Total assets | $74.3M | $113.2M | $171.0M | $348.5M | $495.9M | $539.8M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M | $78.6M |
| Shareholders' equity | $24.1M | $68.5M | $117.3M | $222.4M | $399.7M | $461.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology